Lataa...
Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells
Androgen receptor (AR)-null prostate tumors have been observed in 11–24% of patients. Histone deacetylases (HDACs) are overexpressed in prostate tumors. Therefore, HDAC inhibitors (Jazz90 and Jazz167) were examined in AR-null prostate cancer cell lines (PC3 and DU145). Both Jazz90 and Jazz167 inhibi...
Tallennettuna:
| Julkaisussa: | Pharmaceuticals (Basel) |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7912319/ https://ncbi.nlm.nih.gov/pubmed/33572730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14020103 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|